- Home
- ALVO vs XNCR Comparison
ALVO vs XNCR Comparison
Compare ALVO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALVO | XNCR |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | Luxembourg | United States |
| Employees | 1032 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALVO | XNCR |
|---|---|---|
| Price | $3.60 | $12.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $8.00 | ★ $22.33 |
| AVG Volume (30 Days) | 604.8K | ★ 793.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $21.29 | $4.80 |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $3.03 | $6.92 |
| 52 Week High | $11.85 | $18.69 |
Technical Indicators
Market Signals| Indicator | ALVO | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 48.96 |
| Support Level | $3.03 | $10.93 |
| Resistance Level | $4.17 | $12.87 |
| Average True Range (ATR) | 0.22 | 0.82 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 59.22 | 47.77 |
Price Performance
Historical ComparisonAbout ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.